[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19
February 01, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Le chiffre d’affaires consolidé progresse de 1 %1 à taux de change constants (TCC ; -7 % en CHF), faisant plus que contrebalancer le recul des ventes lié au COVID-19 et l’érosion induite par les...
European Commission approves Roche’s Tecentriq SC, the EU's first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types
January 16, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Subcutaneous (SC) injection offers the potential for a faster, more convenient alternative to intravenous (IV) infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC...
Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform
December 29, 2023 16:30 ET
|
F. Hoffmann-La Roche Ltd
The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease...
FDA grants priority review to Xolair (omalizumab) for children and adults with food allergies based on positive National Institutes of Health phase III study results
December 19, 2023 09:40 ET
|
F. Hoffmann-La Roche Ltd
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposureInterim analysis results from first-of-its-kind phase III OUtMATCH study...
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices
December 15, 2023 01:15 ET
|
F. Hoffmann-La Roche Ltd
Roche named among top three most sustainable healthcare companies in the Dow Jones Sustainability Indices The ranking acknowledges Roche’s commitment to sustainability as an integral part of its...
New data for Roche’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
December 11, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of...
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A
December 09, 2023 11:30 ET
|
F. Hoffmann-La Roche Ltd
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years...
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
December 08, 2023 11:50 ET
|
F. Hoffmann-La Roche Ltd
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive...
Roche’s inavolisib combination reduces the risk of disease progression by 57% in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
December 08, 2023 11:45 ET
|
F. Hoffmann-La Roche Ltd
Inavolisib in combination with palbociclib and fulvestrant more than doubled progression-free survival compared to palbociclib and fulvestrant alone1The inavolisib combination has the potential to...
Roche announces positive Phase III results for inavolisib combination in people with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
December 05, 2023 01:00 ET
|
F. Hoffmann-La Roche Ltd
Phase III (INAVO120) results show that inavolisib in combination with palbociclib and fulvestrant significantly improved progression-free survival in the first-line settingPIK3CA mutations, found in...